HIV

;

Response to request for information on improving integrity & stability of the 340B program

Jul 28, 2023

Given the importance of the 340B program to both HIV treatment and prevention in the United States, we are pleased that you are taking steps to improve the integrity and stability of the program. While the program has grown in recent years, we believe Congress should take steps now to ensure the 340B program works as intended and any abuses are addressed in order to ensure that the 340B program will be on solid ground and available in the future.

read more

Senate testimony on FY 2024 funding for HIV and hepatitis programs

May 18, 2023

Our nation can eliminate both HIV and viral hepatitis, but without an infusion of new resources to accelerate our efforts, we will continue to fall short of these ambitious goals. Current discussions involving budget caps that reduce non-defense discretionary appropriations would have devastating impacts on our nation’s public health system and our ability to respond to these two infectious diseases.

read more

House testimony on FY24 appropriations for HIV and hepatitis programs

Mar 21, 2023

Our nation can eliminate both HIV and viral hepatitis, but without an infusion of new resources to accelerate our efforts, we will continue to fall short of these ambitious goals. Increased investment in surveillance, education, prevention, and care and treatment will ensure we continue to address HIV and viral hepatitis, including taking a syndemic approach to achieve maximum impact. The programs and funding increases detailed below are pivotal to our nation’s ability to end both these potentially deadly infectious diseases.

read more

ABAC letter on the importance of federal programs and funding for ending HIV in the United States

Mar 6, 2023

AIDS Budget and Appropriations Coalition cochairs the HIV+Hepatitis Policy Institute, The AIDS Institute, NASTAD, and AIDS United wrote to the House Appropriations and Senate Appropriations Committees: “While we still do not have a cure or a vaccine, we have the science and tools to eventually end HIV in the U.S. through science-based prevention & treatment progs. However, public health progs across the country must have the sufficient funding and proper policies in place.”

read more

Comments on Medicare national coverage determination for long-acting injectable PrEP

Feb 10, 2023

On behalf of the HIV+Hepatitis Policy Institute, an organization dedicated to promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions, we thank you for this opportunity to comment on a National Coverage Determination (NCD) by the Centers for Medicare and Medicaid Services (CMS) on the use of provider-administered pre-exposure prophylaxis (PrEP). The first provider-administered medication for HIV pre-exposure prophylaxis (Apretude or cabotegravir as PrEP) was approved by the Food and Drug Administration in January 2022. In August 2022, we wrote to you on behalf of 64 organizations to request that CMS quickly and efficiently evaluate provider-administered PrEP for a National Coverage Determination, which is the only pathway to coverage under Medicare Part B. We commend CMS on moving forward with the NCD process and urge CMS to approve the NCD for provider-administered PrEP.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest